Data from both animal as well as human outcome studies encourage a possible additive effect of finerenone to reduce heart and kidney fibrosis as well as improve organ protection when used with SGLT2 inhibitors and possibly GLP-1RAs (155, 156).These drug not only slowed the progression of DKD, but also achieved remarkable efficacy, acting to reduce inflammation and fibrosis within the kidney (156). Here, SLC5A2 is linked to diabetic kidney disease.